International Patent: FAB GLYCOSYLATED ANTI-DPP3 ANTIBODIES AND FORMULATIONS AND DOSAGE AMOUNTS FOR ADMINISTERING AN ANTI-DPP3 ANTIBODY OR FRAGMENT THEREOF TO HUMAN SUBJECTS

GENEVA, Sept. 18 -- 4TEEN4 PHARMACEUTICALS GMBH filed a patent application (EP2026/056178) for “FAB GLYCOSYLATED ANTI-DPP3 ANTIBODIES AND FORMULATIONS AND DOSAGE AMOUNTS FOR ADMINISTERING AN ANTI-DPP3 ANTIBODY OR FRAGMENT THEREOF TO HUMAN SUBJECTS”. With publication no. WO/2026/185437, here are the other details related to the patent application:

Kind: Initial Publication without ISR [A2]

IPC: C07K 16/28

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Disclaimer: Curated by HT Syndication....